Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (467)	2/5/1999 11:51:00 PM
From: yosi s	Read Replies (1) \| Respond to of 1386

Buy low sell high To sell high you got to first buy low.

To: David Israel-Rosen who wrote (467)	2/6/1999 12:08:00 AM
From: yosi s	Respond to of 1386

I have confidence that Pharmos management can put it self back on track. Gets its product rolling .. Sell Alrex to the widest market. Alrex Margins are much better than Lotemax. Get Le Tobra on the market. Any one with projected price for Le tobra. If it is like Alrex??? Then margins are great. I wonder if the new Kit marketed got some better pricing as well. And if PARS get to share that benefit. Pharmos has had some tough growing pains. I am sure that management is going to find the right partner. That is not getting into M&A nor into reorganization, and knows the ins and out of FDA as well as the regulatory agencies in Europe. I also believe that Pharmos can benefit its share holders by being open about its rate of prescription growth, After all companies warn about revenues. Though revenues may be forthcoming, an indirect gauge is prescription rate of growth.